Key result
Bleeding or stroke on OAC creates strong LAAO indications in ~18% of hospitalized NVAF patients.
Why the study?
Data were lacking on the prevalence of potential candidates for percutaneous left atrial appendage occlusion among real-world patients with nonvalvular atrial fibrillation.
Observational (n=980)
No
Almost one in six hospitalized patients with nonvalvular atrial fibrillation meet strong criteria for percutaneous LAAO due to prior major bleeding or stroke on oral anticoagulation.
Answers are grounded in this paper and cite their sources.
Supports LAAO eligibility screening in hospitalized NVAF with prior OAC failure; leaves open prospective outcome validation before practice change.
AIMS: Percutaneous left atrial appendage occlusion (LAAO) is an alternative nonpharmacological therapeutic option for stroke prevention in patients with NVAF. However, no data exist on potential LAAO candidates' prevalence among 'real-world' NVAF patients. This study aimed to investigate the indications for LAAO in hospitalized patients with comorbid nonvalvular atrial fibrillation (NVAF). METHODS: This is a post-hoc analysis of the MISOAC-AF (Motivational Interviewing to Support OAC-AF, ClinicalTrials.gov: NCT02941978), randomized controlled trial, which enrolled NVAF patients hospitalized for any reason in a tertiary cardiology department. In this analysis, patients with a history of major bleeding or stroke under OAC therapy were considered to have a strong indication for LAAO. RESULTS: A total of 980 patients with NVAF were studied (mean age 73.9 ± 10.9 years, 54.7% men). Prior major bleeding occurred in 134 (13.7%) patients (intracranial bleeding in 1%, upper and lower gastrointestinal bleeding in 6.4 and 8.9%, respectively). A total of 58 (5.9%) patients experienced an embolic stroke while being treated using OAC. Overall, either of these events was prevalent in 173 (17.7%) patients, denoting a strong indication for LAAO. CONCLUSION: Almost one out of six patients hospitalized with comorbid NVAF may be considered eligible for percutaneous LAAO for stroke prevention.Trial Identification: NCT02941978, https://clinicaltrials.gov/ct2/show/NCT02941978.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted an observational in Nonvalvular atrial fibrillation (NVAF) (n=980). History of major bleeding or stroke under OAC therapy was evaluated on Prevalence of strong indication for LAAO (prior major bleeding or embolic stroke under OAC). A strong indication for left atrial appendage occlusion was present in 17.7% of hospitalized patients with nonvalvular atrial fibrillation due to prior major bleeding or stroke under OAC.
Synapse has enriched 10 related papers. Consider them for comparative context: